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Diabetic Stem-Cell “Mobilopathy”
John F. DiPersio, M.D., Ph.D.
Hematopoietic stem-cell (HSC) transplantation 
remains the primary curative treatment for pa-
tients with a variety of hematologic cancers. 
Transplantation of either autologous or allogeneic 
stem cells requires the acquisition of sufficient 
numbers of HSCs to ensure rapid and consistent 
trilineage engraftment, thus minimizing extend-
ed periods of pancytopenia after transplantation. 
Methods to optimize peripheralization of HSCs 
boost the number of HSCs that can be obtained 
for transplantation. These methods are based on 
the use of either cytokines alone (granulocyte 
colony-stimulating factor [G-CSF] or granulocyte–
macrophage colony-stimulating factor [GM-CSF]) 
or cytokines plus chemotherapy to induce effec-
tive egress of HSCs from the bone marrow into 
the peripheral blood, where they can be collected 
by means of apheresis. HSCs express CD34 and 
can thereby be captured and measured by means 
of flow cytometry.
G-CSF and GM-CSF have been approved by the 
Food and Drug Administration for autologous 
and allogeneic stem-cell mobilization, but admin-
istration of these cytokines with or without che-
motherapy may still result in failure to mobilize 
sufficient numbers of cells for stem-cell trans-
plantation.1 A disease state caused by failure to 
mobilize (“mobilopathy”) results not only in ad-
ditional cost but also in increased morbidity and 
even the loss of transplantation as a curative op-
tion for some patients. Recently, plerixafor (also 
called AMD3100), a small-molecule inhibitor of 
the CXC chemokine receptor 4 (CXCR4)–CXC 
chemokine ligand 12 (CXCL12) axis, was approved 
for stem-cell mobilization and has resulted in a 
modest reduction in failure rates when combined 
with G-CSF in patients with myeloma and lym-
phoma.2 (CXCL12 is one of the ligands of CXCR4, 
and the CXCR4–CXCL12 axis is a critical tether 
that retains HSCs in the bone marrow and also 
guides their homing to the bone marrow.)
There is considerable variation in the ability 
of the stem cells of patients and healthy donors 
to mobilize. The causes of mobilization failure 
remain unknown, but failure has been associated 
with older age, female sex, exposure to chemo-
therapeutic agents that are toxic to the bone 
marrow, CD34 cells and platelets per cubic milli-
meter of blood prior to mobilization, and genetic 
variants of CXCL12. Researchers’ understanding 
of the mechanisms involved in HSC mobilization 
and the dynamic forces that define the HSC 
niche has been dramatically expanded over the 
past decade.3,4 This niche can be dichotomized 
into vascular and endosteal compartments (Fig. 1). 
The endosteal or osteoblastic niche is defined 
by quiescent HSCs, osteoblasts expressing CXCL12 
and the adhesion molecules vascular-cell adhe-
sion molecule 1 and N-cadherin, supporting 
CD68+ macrophages (which release proteases), 
cytokines, and extracellular matrix proteins.
Recent data suggest that G-CSF mediates the 
profound loss of CXCL12-positive osteoblasts and 
the down-regulation of CXCL12 expressed by 
nestin-expressing CXCL12-positive abundant re-
ticular and mesenchymal cells. These nestin-posi-
tive, CXCL12-positive abundant reticular cells, 
which in part define the vascular niche, are scat-
tered throughout the marrow but primarily local-
ize adjacent to the vascular sinusoids and are 
innervated directly and indirectly by β-adrenergic 
sympathetic nerves. G-CSF induces mobilization 
of HSCs from the endosteal and vascular niches 
through its direct effects on certain macro-
phages and β-adrenergic sympathetic nerves, 
resulting in the loss of osteoblasts and dramatic 
down-regulation of CXCL12 in the osteoblasts 
that remain and in nestin-positive, CXCL12-posi-
tive abundant reticular cells. G-CSF also triggers 
the release of putative and as yet unknown pro-
teases that cleave the multiple tethers (such as 
CXCL12–CXCR4) that hold the HSCs in these 
niches. Most HSCs are located in close proximity 
to nestin-positive, CXCL12-positive abundant re-
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Figure 1. Hematopoietic Stem-Cell Mobilization in the Bone Marrow of Patients with Diabetes.
The bone marrow niche consists of two major elements. The first element is the osteoblastic niche. Osteoblasts ex-
press moderate levels of CXCL12 (pink) and bind hematopoietic stem cells (blue circles) that are primarily quiescent. The 
second element is the vascular niche, which is composed of vascular sinuses; lining endothelial cells; nestin-positive, 
CXCL12-positive abundant reticular (CAR) cells; β3-adrenergic receptors expressed on CAR cells; sympathetic neurons; 
and abundant hematopoietic stem cells. As shown in Panel A, the bone marrow microenvironment in patients with 
diabetes has increased numbers of quiescent hematopoietic stem cells (blue circles) and cycling hematopoietic stem 
cells (conjoined blue forms) and reduced numbers of osteoblasts and increased numbers of sympathetic neurons 
and β3-adrenergic receptors. As shown in Panel B, granulocyte colony-stimulating factor depletes osteoblasts and 
reduces CXCL12 expression in both osteoblasts and CAR cells, resulting in transmigration of hematopoietic stem 
cells into the vascular sinuses (peripheral circulation). Granulocyte colony-stimulating factor induces a similar reduc-
tion of osteoblasts and CXCL12 expression in osteoblasts (white) but no reduction of CXCL12 expression (red) in the 
marrow of patients with diabetes as compared with normal marrow, resulting in a reduction in transmigration and 
mobilization of hematopoietic stem cells associated with CAR cells into the vascular sinuses (peripheral circulation).
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ticular cells that may, possibly through interac-
tion with CXCL12, maintain the quiescence and 
stem-cell–like characteristics of HSCs.
Ferraro et al.5 recently reported that diabetes 
is a disease that both interrupts the dynamic 
anatomy of the niche and induces HSC-indepen-
dent and bone marrow microenvironment–depen-
dent defects in G-CSF–induced HSC mobiliza-
tion. They first showed, in a small and highly 
selected cohort of patients undergoing autolo-
gous transplantation, that elevated blood glucose 
and glycated hemoglobin levels are more com-
mon in patients in whom HSCs failed to mobi-
lize into the peripheral-blood system. They next 
observed impaired G-CSF–induced HSC mobili-
zation in mouse models of diabetes. Although 
the total number and percentages of long-term 
HSCs in the bone marrow of streptozocin-treat-
ed mice (a mouse model of diabetes) were ele-
vated as compared with those of untreated mice, 
there was no commensurate elevation in levels 
of circulating HSCs — suggesting a defect in 
the trafficking of HSCs out of the bone marrow 
at rest. The preference of HSCs for the bone mar-
row in mice with diabetes was lost when they 
were transplanted into healthy mice, further 
demonstrating that the defect was not HSC- 
intrinsic but rather was due to the altered bone 
marrow microenvironment of mice with diabetes.
Consistent with these findings was the ob-
servation by Ferraro et al. that normal HSCs 
homed to the marrow more rapidly and prolifer-
ated (in the marrow) more vigorously when in-
jected into mice with diabetes as compared with 
the behaviors of these cells in healthy mice. 
Treatment of healthy mice with G-CSF resulted 
in the expected loss of osteoblasts and in CXCL12 
expression in osteoblasts and nestin-positive, 
CXCL12-positive abundant reticular cells, com-
mensurate with vigorous HSC mobilization. In 
contrast, treatment of diabetic mice with G-CSF 
resulted in an expected loss of osteoblasts and 
down-regulation of CXCL12 expressed by osteo-
blasts, but no change in the expression of 
CXCL12 by nestin-positive, CXCL12-positive abun-
dant reticular cells, resulting in a dramatic re-
duction in G-CSF–mediated HSC mobilization 
(Fig. 1B).
Defects in HSC mobilization after treatment 
of mice with β3-adrenergic receptor agonists as 
well as studies showing that genetic depletion 
of osteoblasts in mice with diabetes resulted in 
complete elimination of any residual mobilization 
induced by G-CSF all support the authors’ hy-
pothesis that altered G-CSF–induced mobiliza-
tion in mice with diabetes was due to a defect 
in the activation of the sympathetic nervous sys-
tem (in spite of increased numbers of sympa-
thetic nerve fibers in the bone marrow of mice 
with diabetes). This defect results in a function-
al blockade of G-CSF–induced down-regulation 
of CXCL12 in nestin-positive, CXCL12-positive 
abundant reticular cells, the major CXCL12– 
expressing resident cells of the vascular niche. 
The authors suggest that this defect could be 
overcome with the use of plerixafor with or with-
out G-CSF. Since plerixafor is a weaker mobiliz-
ing agent than G-CSF, it is possible but unlikely 
that it can mediate the successful stem-cell mo-
bilization in the patients with diabetes in whom 
stem cells fail to mobilize after the administra-
tion of G-CSF alone. Only future prospective 
clinical trials can answer this question.
One can only assume that many groups will 
now look closely at larger and less selected co-
horts of both patients and healthy donors to see 
whether this preclinical observation holds up 
clinically. If it does, the use of alternative and 
optimal mobilization approaches (G-CSF plus 
plerixafor or G-CSF plus chemotherapy) could 
be used as early treatment in patients with dia-
betes to limit the odds of mobilization failure 
and the number of patients requiring second 
mobilizations or allogeneic stem-cell transplan-
tation for potentially curative therapy.
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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